Carvedilol Tablet, Film Coated
Product Images NDC 51655-713

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 51655-713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 713 52 Master Bottle Label Approval Rev A 05 21)

Label (51655 713 52 Master Bottle Label Approval Rev A 05 21)
Label for Carvedilol 3.125 mg tablets, USP, film-coated, oral dosage form. The package contains 30 tablets and is labeled for prescription use only. The label includes storage instructions, manufacturer Northwind Health Company, LLC, and product NDC 51655-713. Additional details include lot and expiration placeholders.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph depicting percentage mortality over a period of 21 months. Two curves are labeled: one for Placebo and one for Carvedilol. The Carvedilol line shows a consistently lower mortality percentage compared to Placebo. A p-value of 0.0014 is indicated, suggesting statistical comparison between the two groups.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A forest plot showing hazard ratios with confidence intervals for various patient subgroups including gender, age groups, race, diabetic status, ischemic status, heart rate categories, systolic blood pressure levels, and use of spironolactone. The horizontal axis represents the hazard ratio ranging from 0.0 to 2.0, and a vertical dashed line at 1.0 indicates the reference point. Each subgroup's hazard ratio is depicted as a black dot with horizontal lines showing confidence intervals.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph comparing percentage mortality over time in months between Carvedilol treatment and placebo groups. The x-axis represents duration in months (0 to 24), and the y-axis shows mortality percentage (0 to 30%). Two lines indicate lower mortality with Carvedilol versus placebo, including a P-value of 0.03.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A forest plot presenting hazard ratios for various patient subgroups, stratified by factors such as age, gender, timing of randomization, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA for MI, CHF status, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The plot uses horizontal lines and point estimates to illustrate the risk comparisons for each subgroup, with all hazard ratios centered near 1.0.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of carvedilol, displaying its molecular framework with identifiable rings and functional groups consistent with the active ingredient carvedilol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.